Comparative Pharmacology
Head-to-head clinical analysis: AZOLID versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZOLID versus NAPROXEN SODIUM.
AZOLID vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically interfering with peptidoglycan cross-linking.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
2 g intravenously every 6-8 hours; maximum 8 g/day.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
Terminal half-life 1.5-2 hours in normal renal function; prolonged to 4-8 hours in severe renal impairment (CrCl <30 mL/min)
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Clinical Note
moderateFurazolidone + Torasemide
"Furazolidone may increase the hypotensive activities of Torasemide."
Clinical Note
moderateFurazolidone + Travoprost
"Furazolidone may increase the hypotensive activities of Travoprost."
Clinical Note
moderateFurazolidone + Unoprostone
"Furazolidone may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateFurazolidone + Hydrochlorothiazide
"Furazolidone may increase the hypotensive activities of Hydrochlorothiazide."
Renal (80-90% unchanged), biliary/fecal (10-20%)
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID